For help on how to get the results you want, see our search tips.
32 results
Categories
Human Remove Human filter
PIP compliance check
Yes Remove Yes filter
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Kineret, anakinra
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-001212-PIP01-11, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 28/03/2012, Last updated: 19/04/2012, Compliance check: V, 12/12/2014 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Anastrozole
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: Anastrozole, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablets
Decision date: 06/02/2009, Last updated: 23/04/2009, Compliance check: V, 03/04/2009 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cholestagel, Colesevelam hydrochloride
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: Colesevelam hydrochloride, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 19/06/2009, Last updated: 11/08/2009, Compliance check: V, 24/07/2009 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Losartan potassium
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Cardiovascular diseases
PIP number: Losartan potassium, Route(s) of administration: Oral route, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral liquid dosage form
Decision date: 29/02/2008, Last updated: 19/03/2008, Compliance check: V, 06/02/2009 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Sodium benzylpenilloate, benzylpenicilloyl octa- L-lysine
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Diagnostic
PIP number: EMEA-001398-PIP02-13, Route(s) of administration: Skin scarification, Intradermal use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 29/11/2013, Last updated: 06/01/2014, Compliance check: V, 12/09/2014 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): ViraferonPeg, peginterferon alfa-2b
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-000384-PIP01-08, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Powder and solvent for solution for injection in vial and in pre-filled pen
Decision date: 14/10/2008, Last updated: 24/11/2008, Compliance check: V, 17/10/2008 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Adenovirus associated viral vector serotype 2 containing the human RPE65 gene
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Ophthalmology
PIP number: EMEA-001684-PIP01-14, Route(s) of administration: Intraocular use, Pharmaceutical form(s): Solution for injection
Decision date: 02/10/2015, Last updated: 07/03/2019, Compliance check: V, 21/04/2017 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Azelastine (hydrochloride), fluticasone propionate
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000990-PIP02-10, Route(s) of administration: Nasal use, Pharmaceutical form(s): Nasal spray, suspension
Decision date: 06/04/2011, Last updated: 12/05/2011, Compliance check: V, 24/06/2011 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Rizatriptan
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pain
PIP number: EMEA-000084-PIP02-10, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet
Decision date: 28/01/2011, Last updated: 23/02/2011, Compliance check: V, 14/09/2011 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-001792-PIP01-15, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Dispersion for infusion
Decision date: 18/03/2016, Last updated: 25/04/2016, Compliance check: V, 24/03/2017 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tetracaine (hydrochloride), Oxymetazoline hydrochloride
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Anaesthesiology
PIP number: EMEA-001764-PIP03-15, Route(s) of administration: Nasal use, Pharmaceutical form(s): Nasal spray, solution
Decision date: 18/03/2016, Last updated: 25/04/2016, Compliance check: V, 21/04/2017 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Humira, adalimumab
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Dermatology
PIP number: EMEA-000366-PIP04-12, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 03/05/2013, Last updated: 21/06/2013, Compliance check: V, 01/04/2016 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Lantus, insulin glargine
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: Insulin glargine, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection, Solution for injection in a vial, Solution for injection in a cartridge
Decision date: 15/07/2009, Last updated: 16/09/2009, Compliance check: V, 18/11/2011 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Atorvastatin calcium
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: Atorvastatin calcium, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral formulation
Decision date: 20/07/2008, Last updated: 08/09/2008, Compliance check: V, 13/11/2009 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Clindamycin phosphate, Tretinoin
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Dermatology
PIP number: EMEA-000892-PIP01-10, Route(s) of administration: Cutaneous use, Pharmaceutical form(s): Gel
Decision date: 27/08/2010, Last updated: 06/10/2010, Compliance check: V, 10/12/2010 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): misoprostol
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Other
PIP number: EMEA-001159-PIP02-12, Route(s) of administration: Vaginal use, Pharmaceutical form(s): Vaginal delivery system
Decision date: 23/07/2012, Last updated: 23/08/2012, Compliance check: V, 11/10/2012 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Raltegravir, lamivudine
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-001442-PIP01-13, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 13/01/2014, Last updated: 05/02/2014, Compliance check: V, 21/03/2014 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Toujeo (previously Optisulin), insulin glargine
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: Insulin glargine, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection, Solution for injection in a vial, Solution for injection in a cartridge
Decision date: 15/07/2009, Last updated: 16/09/2009, Compliance check: V, 18/11/2011 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Buccolam, Midazolam Hydrochloride
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Neurology
PIP number: EMEA-000395-PIP01-08, Route(s) of administration: Oromucosal use, Pharmaceutical form(s): Oromucosal solution
Decision date: 11/08/2009, Last updated: 22/10/2009, Compliance check: V, 06/08/2010 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tobramycin
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000184-PIP02-14, Route(s) of administration: Inhalation use, Pharmaceutical form(s): Nebuliser solution
Decision date: 06/08/2014, Last updated: 22/08/2014, Compliance check: V, 29/04/2016 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): purified diphtheria toxoid, Purified Tetanus Toxoid, Five component acellular pertussis [Purified Pertussis Toxoid (PT), Purified Filamentous Haemagglutinin (FHA), Purified Fimbriae Types 2 and 3 (FIM), and Purified Pertactin (PRN)], Inactivated poliomyelitis vaccine (Vero) – Type 1 (Mahoney), Type 2 (MEF-1) and Type 3 (Saukett), Purified polyribosylribitol phosphate capsular polysaccharide of Haemophilus influenzae type b covalently bound to Tetanus protein (PRP-T)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Vaccines
PIP number: EMEA-000278-PIP01-08-M01, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Suspension for injection (in a pre-filled syringe), Suspension for injection in a vial
Decision date: 31/03/2009, Last updated: 18/05/2009, Compliance check: V, 18/09/2009 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Human normal immunoglobulin
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-001637-PIP01-13, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 11/03/2014, Last updated: 16/04/2014, Compliance check: V, 16/01/2015 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): PegIntron, peginterferon alfa-2b
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-000071-PIP01-07, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Powder and solvent for solution for injection in vial and in pre-filled pen
Decision date: 15/08/2008, Last updated: 18/09/2008, Compliance check: V, 17/10/2008 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Rebetol, Ribavirin
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Gastroentology-Hepatology
PIP number: Ribavirin, Route(s) of administration: Oral use, Pharmaceutical form(s): Oral solution and Hard Capsules
Decision date: 15/08/2008, Last updated: 18/09/2008, Compliance check: V, 17/10/2008 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Truvada, emtricitabine, tenofovir disoproxil fumarate
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
PIP number: EMEA-001091-PIP02-15, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 03/12/2015, Last updated: 02/02/2016, Compliance check: V, 16/12/2016